T1	Premise 1397 1573	Mean physical function at 12 months was 66 points (95% CI 62·9-70·0) in the 90 mg group and 68 points (64·6-71·4) in the 30 mg group (95% CI of difference -6·6 to 3·3; p=0·52).
T2	Premise 1574 1752	Median time to first skeletal-related event in patients who had such an event was 9·2 months (8·1-10·7) in the 90 mg group and 10·2 months (7·3-14·0) in the 30 mg group (p=0·63).
T3	Premise 1782 1909	eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group.
T4	Claim 1910 2044	Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
R1	Support Arg1:T3 Arg2:T4	
R2	Support Arg1:T2 Arg2:T4	
R3	Support Arg1:T1 Arg2:T4	
